Efficacy and Safety of Introduction Timolol Maleate by Manometer Microneedles among Infantile Hemangioma: A Retrospective Study in China

Abstract

Objective The objective of the study was to compare the effective rate, cure rate, adverse reaction rate, and effective time of three methods in the treatment of infantile hemangioma, hoping to provide reference for improving the clinical therapeutic effect.

Methods This is a retrospective study of 307 infantile hemangioma patients admitted to the Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University, from January 2014 to October 2021. The patients were divided into three groups. In group A, timolol maleate solution was introduced by the nano-microneedle technique (97 cases); in group B, timolol maleate drops dipped in medical swabs were applied (107 cases); and group C patients took propranolol orally (103 cases). The effective rate, cure rate, adverse reaction rate, and effective time of treatment were recorded and compared.

Results The total effective rate, total cure rate, and total adverse reaction rate of the three groups were 87.6, 65.2, and 9.4%, respectively. The results showed that the effective and cure rates of group A were higher than those of group B (92.8 and 76.3%, respectively; p < 0.05), the adverse reaction rate of group C was higher than that of group B (17.5%, p < 0.05), and the effective time of group A was shorter than that of groups B and C. In most patients, symptoms significantly improved within 2 months (p < 0.05).

Conclusion Timolol maleate introduced by nanometer microneedles is an effective and safe treatment for superficial hemangioma in infants with the highest effective and cure rates, lower incidence of adverse reactions, and the shortest effective treatment time.

Keywords

infantile hemangioma - timolol maleate - propranolol - nanometer microneedle

Publication History

Received: 27 December 2022

Accepted: 14 March 2023

Article published online:
01 May 2023

• References

• 1 Leung AKC, Lam JM, Leong KF, Hon KL. Infantile hemangioma: an updated review. Curr Pediatr Rev 2021; 17 (01) 55-69
• 2 Haggstrom AN, Drolet BA, Baselga E. et al; Hemangioma Investigator Group. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150 (03) 291-294
• 3 Zheng JW, Wang XK, Qin ZP. et al. Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas. Shanghai Kou Qiang Yi Xue 2016; 25 (03) 257-260
• 4 Hochman M, Adams DM, Reeves TD. Current knowledge and management of vascular anomalies: I. Hemangiomas. Arch Facial Plast Surg 2011; 13 (03) 145-151
• 5 Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011; 223 (04) 330-334
• 6 Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128 (02) 255-256
• 7 Drolet BA, Frommelt PC, Chamlin SL. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131 (01) 128-140
• 8 Hoeger PH, Harper JI, Baselga E. et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174 (07) 855-865
• 9 Ye XX, Jin YB, Lin XX. et al. Topical timolol in the treatment of periocular superficial infantile hemangiomas: a prospective study. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 2012; 28 (03) 161-164
• 10 Chakkittakandiyil A, Phillips R, Frieden IJ. et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29 (01) 28-31
• 11 Li X, Zhao R, Qin Z. et al. Microneedle pretreatment improves efficacy of cutaneous topical anesthesia. Am J Emerg Med 2010; 28 (02) 130-134
• 12 Yu CQ, Xu XG, Chen HD, Li YH. Clinical efficacy and safety of nano-microneedle-assisted phenylethyl resorcinol for the treatment of infraorbital dark circles. J Cosmet Dermatol 2021; 20 (03) 884-889
• 13 Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg 1997; 99 (05) 1301-1308
• 14 Li XH, Li CX, Ling B, Gong ZC. Effect of topical timolol and oral use propranolol for the treatment of superficialinfantile hemangioma: a systematic review and Meta-analysis. J Oral Maxillofac Surg 2021; 31 (02) 90-96
• 15 Colmant C, Powell J. Medical management of infantile hemangiomas: an update. Paediatr Drugs 2022; 24 (01) 29-43
• 16 Krowchuk DP, Frieden IJ, Mancini AJ. et al; Subcommittee on the Management of Infantile Hemangiomas. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics 2019; 143 (01) e20183475
• 17 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24) 2649-2651
• 18 Xu Y, Ma R, Juliandri J. et al. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: a randomized, self-controlled, split-face study. Medicine (Baltimore) 2017; 96 (19) e6897
• 19 Cheng M, Wang X. Efficacy analysis of nanoneedle introduction of 0.5% timolol maleate in the treatment of superficial infantile hemangioma [C]. Paper presented at: The 14th Chinese Academic Conference on Oral and Maxillofacial Surgery; Chongqing, October 18, 2018: 594-595